Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Melga, P.
Right arrow Articles by Prando, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Melga, P.
Right arrow Articles by Prando, R.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 20, Issue 1 55-58, Copyright © 1997 by American Diabetes Association


ARTICLES

Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis

P Melga, C Mansi, E Ciuchi, R Giusti, L Sciaba and R Prando
Department of Endocrine and Metabolic Sciences, University of Genoa, Italy.

OBJECTIVE: We evaluated the effect of chronic administration of levosulpiride, a prokinetic drug that is a selective antagonist for D2 dopamine receptors, on the glycemic control of IDDM subjects. RESEARCH DESIGN AND METHODS: The study was performed on 40 long-standing IDDM subjects with clinical signs of autonomic neuropathy and delayed gastric emptying. Gastric emptying time and glycemic parameters (diurnal glycemic profile and HbA1c) were checked under double-blind conditions before and after the administration of levosulpiride at the dosage of 25 mg t.i.d. orally for 6 months, or placebo. RESULTS: No significant differences were noted in the glycemic and HbA1c values before and after 6 months of placebo administration. In contrast, after 6 months of levosulpiride, glycemic control had improved (HbA1c 6.7 +/- 0.4 and 5.7 +/- 0.3%, P < 0.01; mean daily glycemia 10.9 +/- 0.8 and 8.8 +/- 0.4 mmol/l, P < 0.05, at the start and at the end of the study), while the dosage of injected insulin (0.65 +/- 0.02 IU.kg-1.day-1) and the number of severe hypoglycemic episodes remained unchanged. After 6 months of levosulpiride therapy, the time of gastric emptying was significantly reduced from 321 +/- 14 to 261 +/- 9 min (P < 0.001) and dyspeptic symptoms had improved. CONCLUSIONS: Our results show the importance of gastric emptying in the maintenance of glycemic control and the usefulness of chronic administration of levosulpiride in diabetic subjects with gastroparesis.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
GutHome page
H. Abrahamsson
Treatment options for patients with severe gastroparesis
Gut, June 1, 2007; 56(6): 877 - 883.
[Full Text] [PDF]


Home page
Diabetes CareHome page
Z. Lin, J. Forster, I. Sarosiek, and R. W. McCallum
Treatment of Diabetic Gastroparesis by High-Frequency Gastric Electrical Stimulation
Diabetes Care, May 1, 2004; 27(5): 1071 - 1076.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
P. F Lata and D. L W. Pigarelli
Chronic Metoclopramide Therapy for Diabetic Gastroparesis
Ann. Pharmacother., January 1, 2003; 37(1): 122 - 126.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
C. K. Rayner, M. Samsom, K. L. Jones, and M. Horowitz
Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control
Diabetes Care, February 1, 2001; 24(2): 371 - 381.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.